FOLH1 and neoplasm: Another target on tumour ECs, namely human prostate‐specific membrane antigen (hPSMA), has also been used as a target for CAR‐T cells and shown to recognize and ablate PSMA‐positive vessels and deplete tumour cells in mice models.43